Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Carmot Therapeutics Inc.
Headquarters: Berkeley, CA, United States of America
Website: N/A
Year Founded: 2008
Status: Acquired
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Feb 12, 2025
Management Tracks
New CEOs at Aro and Navigator
Plus: Arbuckle retiring from Vertex, and updates from Lb, Glox, Titan and more
BioCentury | Jan 11, 2025
Finance
Metsera, Maze will play canary in the IPO coal mine
Pair of Arch, Ra portfolio companies file to list on NASDAQ
BioCentury | Dec 17, 2024
Product Development
Obesity newcos aim for differentiation
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
BioCentury | Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
BioCentury | Nov 20, 2024
Management Tracks
Latigo names Timothy Walbert chair
Plus: Heather Turner to lead neurology play LB, and updates from Mirai Bio and Diakonos
BioCentury | Nov 15, 2024
Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
BioCentury | Aug 22, 2024
Management Tracks
Blank slate at BioMarin for Sabry as dealmaker gets back to biotech
Company also adds Friberg to lead R&D, continuing the rebuild of its leadership team with former Genentech, Roche, Amgen execs
BioCentury | Jul 29, 2024
Management Tracks
Carmot vet Eric Cox to lead commercial at Zealand
Plus: Mind Medicine hires Fagan and updates from PK and Evexta
Items per page:
1 - 10 of 42